Glaxo, Theravance Win Approval for Lung Disease Treatment

GlaxoSmithKline Plc and Theravance Inc. won U.S. approval of their once-daily drug Breo Ellipta to treat a lung disorder that is the third-leading cause of death.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.